Work

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Year: 2023

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2023-179577

Authors: Matthew S Davids, Yesid Alvarado Valero, Catherine Diefenbach, Daniel N. Egan, Shira N. Dinner, Monzr M. Al Malki, Kebede Begna, Avyakta Kallam, Sameem Abedin, Rachel Cook, Nathalie Javidi-Sharifi, Edward Dominguez, Lu Miao, Richard G Ghalie, Alexey Danilov

Institutions: Harvard University, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, NYU Langone Health, New York University, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, City Of Hope National Medical Center, City of Hope, Mayo Clinic, Nebraska Medical Center, University of Nebraska Medical Center, Medical College of Wisconsin, Oregon Health & Science University, MEI Pharma (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389243050

Cites:

Cited by: 4

Related to: 10